» Articles » PMID: 37605079

Postacute Sequelae of COVID-19 at 2 Years

Overview
Journal Nat Med
Date 2023 Aug 21
PMID 37605079
Authors
Affiliations
Soon will be listed here.
Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can lead to postacute sequelae in multiple organ systems, but evidence is mostly limited to the first year postinfection. We built a cohort of 138,818 individuals with SARS-CoV-2 infection and 5,985,227 noninfected control group from the US Department of Veterans Affairs and followed them for 2 years to estimate the risks of death and 80 prespecified postacute sequelae of COVID-19 (PASC) according to care setting during the acute phase of infection. The increased risk of death was not significant beyond 6 months after infection among nonhospitalized but remained significantly elevated through the 2 years in hospitalized individuals. Within the 80 prespecified sequelae, 69% and 35% of them became not significant at 2 years after infection among nonhospitalized and hospitalized individuals, respectively. Cumulatively at 2 years, PASC contributed 80.4 (95% confidence interval (CI): 71.6-89.6) and 642.8 (95% CI: 596.9-689.3) disability-adjusted life years (DALYs) per 1,000 persons among nonhospitalized and hospitalized individuals; 25.3% (18.9-31.0%) and 21.3% (18.2-24.5%) of the cumulative 2-year DALYs in nonhospitalized and hospitalized were from the second year. In sum, while risks of many sequelae declined 2 years after infection, the substantial cumulative burden of health loss due to PASC calls for attention to the care needs of people with long-term health effects due to SARS-CoV-2 infection.

Citing Articles

SARS-CoV-2 spike peptide analysis reveals a highly conserved region that elicits potentially pathogenic autoantibodies: implications to pan-coronavirus vaccine development.

Diaz M, Mikulski Z, Leaman D, Gandarilla A, Da Silva N, Verkoczy A Front Immunol. 2025; 16:1488388.

PMID: 40070822 PMC: 11893414. DOI: 10.3389/fimmu.2025.1488388.


Five Years of Long COVID Syndrome: An Updated Review on Cardiometabolic and Psychiatric Aspects.

Sakellaropoulos S, Sakellaropoulos P, Steinberg B, Rogers C, Ismael O, Scholl E Cardiol Res. 2025; 16(2):81-85.

PMID: 40051665 PMC: 11882234. DOI: 10.14740/cr2014.


Incidence and factors associated with SARS-CoV-2 infection and re-infection among people experiencing homelessness in Toronto, Canada: A prospective cohort study.

Richard L, Carter B, Liu M, Nisenbaum R, Hwang S PLoS One. 2025; 20(2):e0319296.

PMID: 40019892 PMC: 11870375. DOI: 10.1371/journal.pone.0319296.


Novel Oronasal Drainage for Long COVID: Proposed Mechanisms-Case Report.

Lorenz C, Frankenberger R Viruses. 2025; 17(2).

PMID: 40006965 PMC: 11861156. DOI: 10.3390/v17020210.


Functional Capacity Impairment in Long COVID After 17 Months of Severe Acute Disease.

Borges F, Braga A, Viana B, Valente J, Bemfica J, SantAnna T Int J Environ Res Public Health. 2025; 22(2).

PMID: 40003501 PMC: 11855803. DOI: 10.3390/ijerph22020276.


References
1.
Davis H, McCorkell L, Vogel J, Topol E . Author Correction: Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023; 21(6):408. PMC: 10408714. DOI: 10.1038/s41579-023-00896-0. View

2.
Al-Aly Z, Xie Y, Bowe B . High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021; 594(7862):259-264. DOI: 10.1038/s41586-021-03553-9. View

3.
Xie Y, Xu E, Bowe B, Al-Aly Z . Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022; 28(3):583-590. PMC: 8938267. DOI: 10.1038/s41591-022-01689-3. View

4.
Xie Y, Xu E, Al-Aly Z . Risks of mental health outcomes in people with covid-19: cohort study. BMJ. 2022; 376:e068993. PMC: 8847881. DOI: 10.1136/bmj-2021-068993. View

5.
Xie Y, Al-Aly Z . Risks and burdens of incident diabetes in long COVID: a cohort study. Lancet Diabetes Endocrinol. 2022; 10(5):311-321. PMC: 8937253. DOI: 10.1016/S2213-8587(22)00044-4. View